Pharmacogene Variants Associated with Liver Transplant in a Twelve-Year Clinical Follow-Up
Some gene polymorphisms have been previously associated individually with tacrolimus efficacy and toxicity, but no long-term study to determine the role of pharmacogene variants in the clinical evolution of liver-transplanted patients has been addressed so far. In the present work, we analyzed the relation between highly-evidenced genetic polymorphisms located in relevant pharmacogenes and the risk of suffering premature death and other comorbidities such as cancer, diabetes mellitus, arterial hypertension, graft rejection, infections and nephrotoxicities in a cohort of 87 patients (8 were excluded due to early loss of follow-up) transplanted at Hospital La Fe in Valencia (Spain) during a 12-year follow-up. Employing a logistic regression model with false discovery rate penalization and Kaplan-Meier analyses, we observed significant association between survival rates and metabolizer genes. In this sense, our results show an association between MTHFR gene variants in donor rs1801133 (HR: 7.90; p-value: 0.032) and recipient rs1801131 (HR: 7.34; p-value: 0.036) and the group of patients who died during the follow-up period, supporting the interest of confirming these results with larger patient cohorts. In addition, donor polymorphisms in UGT1A9 metabolizer gene rs6714486 (OR: 0.13; p-value: 0.032) were associated with a lower risk of suffering from de novo cancer. Genetic variants in CYP2B6 metabolizer gene rs2279343 demonstrated an association with a risk of infection. Other variants in different locations of SLCO1A2, ABCC2 and ABCB1 transporter genes were associated with a lower risk of suffering from type 2 diabetes mellitus, chronic and acute nephrotoxicities and arterial hypertension. Results suggest that pharmacogenetics-derived information may be an important support for personalized drug prescription, clinical follow-up and the evolution of liver-transplanted patients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Pharmaceutics - 14(2022), 2 vom: 03. Feb. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sendra, Luis [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 01.03.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/pharmaceutics14020354 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM337455929 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM337455929 | ||
003 | DE-627 | ||
005 | 20231225234440.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/pharmaceutics14020354 |2 doi | |
028 | 5 | 2 | |a pubmed24n1124.xml |
035 | |a (DE-627)NLM337455929 | ||
035 | |a (NLM)35214086 | ||
035 | |a (PII)354 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sendra, Luis |e verfasserin |4 aut | |
245 | 1 | 0 | |a Pharmacogene Variants Associated with Liver Transplant in a Twelve-Year Clinical Follow-Up |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 01.03.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Some gene polymorphisms have been previously associated individually with tacrolimus efficacy and toxicity, but no long-term study to determine the role of pharmacogene variants in the clinical evolution of liver-transplanted patients has been addressed so far. In the present work, we analyzed the relation between highly-evidenced genetic polymorphisms located in relevant pharmacogenes and the risk of suffering premature death and other comorbidities such as cancer, diabetes mellitus, arterial hypertension, graft rejection, infections and nephrotoxicities in a cohort of 87 patients (8 were excluded due to early loss of follow-up) transplanted at Hospital La Fe in Valencia (Spain) during a 12-year follow-up. Employing a logistic regression model with false discovery rate penalization and Kaplan-Meier analyses, we observed significant association between survival rates and metabolizer genes. In this sense, our results show an association between MTHFR gene variants in donor rs1801133 (HR: 7.90; p-value: 0.032) and recipient rs1801131 (HR: 7.34; p-value: 0.036) and the group of patients who died during the follow-up period, supporting the interest of confirming these results with larger patient cohorts. In addition, donor polymorphisms in UGT1A9 metabolizer gene rs6714486 (OR: 0.13; p-value: 0.032) were associated with a lower risk of suffering from de novo cancer. Genetic variants in CYP2B6 metabolizer gene rs2279343 demonstrated an association with a risk of infection. Other variants in different locations of SLCO1A2, ABCC2 and ABCB1 transporter genes were associated with a lower risk of suffering from type 2 diabetes mellitus, chronic and acute nephrotoxicities and arterial hypertension. Results suggest that pharmacogenetics-derived information may be an important support for personalized drug prescription, clinical follow-up and the evolution of liver-transplanted patients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a ABC | |
650 | 4 | |a CYP | |
650 | 4 | |a SLCO | |
650 | 4 | |a immunosuppressant | |
650 | 4 | |a pharmacogenetics | |
700 | 1 | |a Olivera, Gladys G |e verfasserin |4 aut | |
700 | 1 | |a López-Andújar, Rafael |e verfasserin |4 aut | |
700 | 1 | |a Serrano, Cristina |e verfasserin |4 aut | |
700 | 1 | |a Rojas, Luis E |e verfasserin |4 aut | |
700 | 1 | |a Montalvá, Eva María |e verfasserin |4 aut | |
700 | 1 | |a Herrero, María José |e verfasserin |4 aut | |
700 | 1 | |a Aliño, Salvador F |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmaceutics |d 2010 |g 14(2022), 2 vom: 03. Feb. |w (DE-627)NLM204303303 |x 1999-4923 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2022 |g number:2 |g day:03 |g month:02 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/pharmaceutics14020354 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2022 |e 2 |b 03 |c 02 |